P427 Impact of curcuma longa on clinical activity and inflammatory markers in patients with active ulcerative colitis: a double-blind randomised placebo-controlled trial
S. Kumar1, U. Dutta1, J. Shah*1, P. Singh1, C. Vaishnavi1, K. K. Prasad1, K. Singh1
1PGIMER, Gastroenterology, Chandigarh, India
Curcumin, biologically active substance of
The study was a single-centre, double-blind, randomised, placebo-controlled trial in which patients with active UC (UCDAI ≥3) were enrolled. The two arms of the study were mesalamine 2.4 g/day with powder of Curcuma longa 10 g/day (
Of 150 patients of UC screened, 53 patients fulfilled inclusion criteria and were randomised. Though more patients in CL group achieved primary outcome compared with placebo, it was not statistically significant [60.7% vs. 52%;
Curcuma longa can reduce the disease activity as assessed by UCDAI, FC, and histological examination when added to standard therapy. It is a low-cost, natural, and easily available add on therapy to reduce the disease activity.